Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Pieris Pharmaceuticals, Inc is a biotechnology business based in the US. Pieris Pharmaceuticals shares (PIRS) are listed on the NASDAQ and all prices are listed in US Dollars. Pieris Pharmaceuticals employs 114 staff and has a trailing 12-month revenue of around USD$44.7 million.
|Latest market close||USD$2.93|
|52-week range||USD$1.6 - USD$4.3|
|50-day moving average||USD$2.57|
|200-day moving average||USD$2.8232|
|Wall St. target price||USD$7.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.767|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-09)||N/A|
|1 month (2020-12-16)||0.34%|
|3 months (2020-10-20)||25.75%|
|6 months (2020-07-16)||N/A|
|1 year (2020-01-16)||N/A|
|2 years (2019-01-16)||N/A|
|3 years (2018-01-16)||N/A|
|5 years (2016-01-16)||N/A|
|Revenue TTM||USD$44.7 million|
|Gross profit TTM||USD$46.3 million|
|Return on assets TTM||-12.28%|
|Return on equity TTM||-73.37%|
|Market capitalisation||USD$158.4 million|
TTM: trailing 12 months
There are currently 2.0 million Pieris Pharmaceuticals shares held short by investors – that's known as Pieris Pharmaceuticals's "short interest". This figure is 7.9% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting Pieris Pharmaceuticals shares can be evaluated.
Pieris Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Pieris Pharmaceuticals shares currently shorted divided by the average quantity of Pieris Pharmaceuticals shares traded daily (recently around 377582.8358209). Pieris Pharmaceuticals's SIR currently stands at 5.36. In other words for every 100,000 Pieris Pharmaceuticals shares traded daily on the market, roughly 5360 shares are currently held short.
However Pieris Pharmaceuticals's short interest can also be evaluated against the total number of Pieris Pharmaceuticals shares, or, against the total number of tradable Pieris Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pieris Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Pieris Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0397% of the tradable shares (for every 100,000 tradable Pieris Pharmaceuticals shares, roughly 40 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pieris Pharmaceuticals.
Find out more about how you can short Pieris Pharmaceuticals stock.
We're not expecting Pieris Pharmaceuticals to pay a dividend over the next 12 months.
Pieris Pharmaceuticals's shares were split on a 2:1 basis on 8 December 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Pieris Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Pieris Pharmaceuticals shares which in turn could have impacted Pieris Pharmaceuticals's share price.
Over the last 12 months, Pieris Pharmaceuticals's shares have ranged in value from as little as $1.6 up to $4.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pieris Pharmaceuticals's is 1.4549. This would suggest that Pieris Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.